NHI.no
Annonse
Informasjon

Kreft i skjoldkjertelen, tyreoideakreft

Kreft i skjoldkjertelen, glandula thyreoidea, forekommer relativt sjelden og utgjør omtrent én prosent av alle krefttilfeller i Norge. Bare et fåtall av disse kreftsvulstene har en aggressiv vekst.

Kreft i skjoldkjertelen gir som regel en smertefri hevelse i skjoldkjertelen.

Sist oppdatert:

11. mars 2022

Dette dokumentet er basert på det profesjonelle dokumentet Thyroideakreft . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for utredning, behandling og oppfølgning av kreft i skjoldbruskkjertelen. Nasjonale faglige retningslinjer, 06/2017. helsedirektoratet.no
  2. Tangerud Å, Sigstad E, Fagerlid KH, Paulsen TH, Norheim I. Knuter i tyreoidea - utredning og oppfølging. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0186 DOI
  3. Kreftregisteret. Cancer in Norway 2020. Oslo: Kreftregisteret, 2021. www.kreftregisteret.no. www.kreftregisteret.no
  4. Deng Y, Li HT, Wang M, et al. Global Burden of Thyroid Cancer From 1990 to 2017. JAMA Netw Open 2020; 3: e208759. doi:10.1001/jamanetworkopen.2020.8759 DOI
  5. Feng X, Wang F, Yang W, et al. Association Between Genetic Risk, Adherence to Healthy Lifestyle Behavior, and Thyroid Cancer Risk. JAMA Netw Open 2022; 5: E2246311. pmid:36508215 PubMed
  6. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212. PubMed
  7. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 2017; 317: 1338-48. pmid:28362912 PubMed
  8. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133. pmid:26462967 PubMed
  9. Datta R. Thyroid cancer. BMJ Best Practice, last reviewed December 2018. bestpractice.bmj.com
  10. McCartney CR, Stukenborg GJ. Decision analysis of discordant thyroid nodule biopsy guideline criteria. J Clin Endocrinol Metab 2008; 93: 3037-44. PubMed
  11. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N Engl J Med 2022; 386: 923.932. pmid:35263518 PubMed
  12. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134. pmid:22025146 PubMed
  13. Elisei R1, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2014; 32: 1864. pmid:24002501 PubMed
  14. Tuttle RM, Ross DS, Mulder JE. Differentiated thyroid cancer: Overview of management. UpToDate. Last updated May 12, 2016. www.uptodate.com
  15. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30 . PMID: 25671254 PubMed
  16. Brose MS, Nutting CM, Jarzab B et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-28. pmid:24768112 PubMed
  17. Viola D, Valerio L, Molinaro E et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 2016; 23: 185-205. pmid:27207700 PubMed
  18. Lin JS, Bowles EJA, Williams SB et al. Screening for Thyroid Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 317: 1888-903. pmid:28492904 PubMed
Annonse
Annonse